Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
J B Chemicals & Pharmaceuticals Ltd

| Q3 FY26 Earnings Conference Call

NEUTRAL SENTIMENT

Report Source

⬤21st Jan 26

Summary : J.B. Pharma delivered strong Q3 FY'26 results, driven by domestic outperformance and international rebound, while managing merger progress.

Management Perspective positive : Management consistently highlighted strong performance, outperformance against market, sustained momentum, robust growth, and good order books across segments.

Concall Report Analysis & Insights

Business Overview

  1. Q3 FY'26 revenue grew 11% to INR1,065 crore.
  2. Operating EBITDA increased 13% to INR305 crore, margin 28.7%.
  3. Net profit rose 22% to INR198 crore.
  4. Gross margins expanded 200 bps to 69.1% due to product mix.
  5. Domestic business grew 10% to INR620 crore, fastest in top 25 Indian pharma.
  6. International operations grew 12% to INR445 crore, driven by formulations.

Future Growth Prospects

  1. Domestic business expected to grow above Indian pharma market.
  2. Guidance for domestic growth 12-14%, outperforming market by 200-300 bps.
  3. CDMO business projected to grow 10-12% for FY'27.
  4. International business expected to achieve high single-digit growth.
  5. Ophthalmology business targets double-digit growth, INR17-18 crore monthly run rate.

Management Insights

  1. Company delivered strong Q3 FY'26 performance with robust growth.
  2. Maintained position as one of India's fastest-growing pharma companies.
  3. Gross margins improved due to product mix, pricing, and stable raw materials.
  4. Reiterated FY'26 operating margin guidance of 27-29%.
  5. Domestic price hike for the quarter was approximately 7%.
  6. Merger with Torrent is progressing, expected in Q4.
  7. No substantial impact from new labor law code.
  8. Debt repaid, surplus cash invested for higher treasury income.

Signs of Skepticism

  1. Merger timeline with Torrent is vague, 6-9 months post Q4 closure.
  2. Management unwilling to discuss potential merger synergies.
  3. CDMO revenue remained nearly flat despite overall strong performance.
  4. Domestic growth slightly slower due to acute gastro portfolio slowdown.

Risk Factors

  1. Forward-looking statements involve inherent risks and uncertainties.
  2. March is a soft month for Indian pharma due to distributor inventory.
  3. Slowdown observed in the acute gastro business portfolio.
  4. Merger with Torrent has an uncertain timeline post Q4 closure.

Good To Know

  1. Interim dividend announcement is pending, decision to be made.
  2. Merger with Torrent expected to close in Q4 FY'26.
  3. Potential INR40 crore ESOP charge if change of control occurs in Q4.
  4. Other income increased significantly due to treasury investments.
  5. Company has successfully repaid all its outstanding debt.

Key Drivers

  1. Outperforming Indian domestic market growth.
  2. Strong international order book for Q4.
  3. Growth in chronic and ophthalmology.
  4. Successful Torrent merger completion.

Key Analyst Discussions

Competitive Environment

  1. Fastest-growing company among top 25 in Indian pharma market.
  2. Outperformed Indian pharma market growth (12% vs 9%).
  3. Six major brands now rank in the top 300 Indian pharma brands.

Market Trends & Consumer Behavior

  1. March is typically a soft month for Indian pharma due to inventory.
  2. Overall domestic growth remains higher than the industry average.
  3. Chronic portfolio performing well, acute gastro showing slowdown.

Financial Highlights

  1. Domestic price hike for the quarter was close to 7%.
  2. Gross margin improvement attributed to product mix and stable raw materials.
  3. Operating EBITDA margin guidance of 27-29% for FY'26 reiterated.
  4. CDMO run rate expected at INR115-120 crore quarterly.
  5. Increased other income due to treasury investments from repaid debt.

Product Composition

  1. Improved gross margins driven by attractive product mix.
  2. Chronic portfolio contributes significantly to India business.
  3. Ophthalmology business includes strong chronic and glaucoma portfolios.

Strategic Considerations

  1. Torrent merger expected to close in Q4, integration 6-9 months.
  2. Management declined to comment on potential merger synergies.
  3. Company aims for high single-digit international business growth.